C4 Therapeutics CCCC 深 沪
已收盘 08-14 16:00:00 美东时间
4.24
+0.160
+3.92%
华盛通- 最 高4.315
- 今 开4.07
- 成交量 339.90万股
- 最 低 3.895
- 昨 收 4.08
- 总市值 4.69亿
- 52周最高 5.17
- 市盈率 静 --
- 换手率 3.07%
- 52周最低 1.6901
- 委 比 -41.93%
- 总股本 1.11亿
- 历史最高 51.21
- 量 比 1.39
- 振 幅 10.29%
- 历史最低 1.06
- 每 手 1
- 风险率 0.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多C4 Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
C4 Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
08-12 00:58
C4 Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate, Sales $6.641M Beat $4.000M Estimate
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 51.35 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $6.641 million...
08-11 19:34
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics reported progress on its cemsidomide program, including Phase 2 MOMENTUM trial and Phase 1b trials in combination with elranatamab and standard of care therapies, with data expected in 2027. The company highlighted cemsidomide's differentiated safety and anti-myeloma activity in heavily pretreated patients, supporting its potential as a best-in-class therapy. Financially, Q2 2026 revenue increased to $6.6 million due to the Roche ...
08-11 11:00
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics, Inc. (Nasdaq: CCCC) announced the grant of non-qualified stock options to purchase 162,880 shares of its common stock to a new employee on August 10, 2026. The options, priced at the closing price on the grant date, vest over four years with 25% after the first year and the rest in monthly installments. C4T is a clinical-stage biopharmaceutical company advancing targeted protein degradation science to develop innovative medicines...
08-10 20:01
C4 Therapeutics To Present Further Analysis From Fully Enrolled Phase 1 Trial Of Cemsidomide In Combination With Dexamethasone For Treatment Of RRMM At EHA 2026 Congress
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well Tolerated With Minimal Discontinuations and Dose Reductions Related to Safety or Tolerability Dat...
06-11 19:12
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
Cemsidomide, a next-generation oral IKZF1/3 degrader, demonstrated a 53% overall response rate (ORR) at the 100 µg recommended Phase 2 dose (RP2D) in patients with relapsed/refractory multiple myeloma (RRMM). The treatment was well-tolerated with minimal discontinuations or dose reductions. Data from the Phase 1 trial support its development as a potential best-in-class therapy, showing durable responses and encouraging activity across subgroups,...
06-11 11:00
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
BMS多发性骨髓瘤III期数据亮眼 C4 Therapeutics受提振大涨
百时美施贵宝日前公布了其在研药物美齐格米德的III期临床试验阳性数据。结果显示，该联合疗法将复发或难治性多发性骨髓瘤患者的疾病进展或死亡风险降低了52%。这...
05-30 03:49
Bristol-Myers multiple myeloma data boosts C4
C4 Therapeutics (CCCC) reached a 52-week high on Friday after a treatment developed by Bristol-Myers Squibb (BMY), similar to the company’s lead candidate, generated impressive survival data in a late...
05-30 02:27
